Peptide Bbeta(15-42) preserves endothelial barrier function in shock.

Vascular permeability is a major contributor to shock pathogenesis. Endothelial cell junctions, particularly those involving VE-cadherin, play a central role in maintaining barrier integrity. RhoGTPases regulate these junctions, and their dysregulation can lead to fluid leakage into tissues. Current treatments for shock do not fully address the molecular mechanisms behind barrier dysfunction. Prior research has shown that thrombin and LPS can disrupt endothelial barriers. However, the role of specific signaling pathways in stabilizing these barriers remains unclear. No prior work had resolved the potential of fibrin-derived peptides to influence vascular integrity. This gap motivated the investigation of Bbeta15-42 as a candidate for barrier preservation. The need for targeted interventions in shock management remains unmet.

This study aimed to evaluate the effect of Bbeta15-42 on endothelial barrier function in shock models. The researchers focused on Dengue shock syndrome and LPS-induced lung injury. They hypothesized that Bbeta15-42 could reduce vascular leak and mortality. The study sought to determine the molecular mechanisms behind the protective effects of the peptide. The researchers also aimed to confirm the role of Fyn kinase in mediating these effects. The study was driven by the need for new therapeutic strategies in shock treatment. The investigation included both in vivo and in vitro models to validate the findings. The ultimate goal was to establish Bbeta15-42 as a potential adjuvant therapy.

The researchers used animal models of Dengue shock syndrome and LPS-induced lung injury. They administered Bbeta15-42 intravenously to rats and mice. Vascular leak was measured using Evans Blue dye extravasation. Endothelial cell stress fiber formation was assessed using immunostaining. Myosin light chain phosphorylation was analyzed via Western blot. RhoA activation was evaluated using pull-down assays. The interaction between Fyn and VE-cadherin was studied using co-immunoprecipitation. The study compared wild-type and Fyn(-/-) mice to assess the role of Fyn in the peptide's effects.

Bbeta15-42 significantly reduced vascular leak in Dengue shock syndrome models. The peptide also decreased mortality in these animals. In LPS-treated rats, Bbeta15-42 reduced lung edema and protein leakage. The peptide prevented thrombin-induced stress fiber formation in endothelial cells. It also inhibited myosin light chain phosphorylation and RhoA activation. Bbeta15-42 caused Fyn to dissociate from VE-cadherin junctions. Instead, Fyn associated with p190RhoGAP, an inhibitor of RhoA. In Fyn(-/-) mice, the protective effects of Bbeta15-42 were absent.

The authors propose that Bbeta15-42 preserves endothelial barriers by modulating Fyn activity. The peptide's protective effects depend on Fyn's interaction with p190RhoGAP. The study suggests that Bbeta15-42 could be an adjuvant in shock treatment. The findings support the idea that Bbeta15-42 is a signaling molecule. The researchers suggest that the peptide's mechanism involves RhoA inhibition. The study highlights the role of Fyn in endothelial barrier regulation. The results indicate that Bbeta15-42 may reduce mortality in shock. The authors conclude that the peptide has therapeutic potential in vascular leak conditions.